The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Imatinib Actavis



Actavis Group hfEU/1/13/825/019-023

Main Information

Trade NameImatinib Actavis
Active SubstancesImatinib mesylate
Dosage FormCapsule, hard
Licence HolderActavis Group hf
Licence NumberEU/1/13/825/019-023

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE01 imatinib

Status

License statusWithdrawn
Withdrawn Date16/05/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal products subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back